Amgen Stock Price

-0.55 (-0.23%)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Amgen Inc AMGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
-0.55 -0.23% 241.00 0.00 0.00 0.00 241.55 08:41:16
Bid Price Ask Price Spread Spread % News
241.00 241.67 0.67 0.28% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
27 453 $ 241.00 $ 109,173 2,502,537 177.05 - 264.97
Last Trade Time Type Quantity Stock Price Currency
08:32:24 49 $ 241.00 USD

Amgen Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 141.15B 585.69M 584.29M $ 23.36B $ 6.99B 12.89 20.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ 5.80 2.41% - -

more financials information »

Amgen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AMGN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week245.63249.02239.105243.861,980,902-4.63-1.88%
1 Month250.65262.815239.105250.482,027,261-9.65-3.85%
3 Months234.43264.97213.8601237.792,571,8596.572.8%
6 Months231.41264.97177.05223.032,925,8029.594.14%
1 Year183.04264.97177.05219.332,680,58857.9631.67%
3 Years173.87264.97163.31195.632,888,15167.1338.61%
5 Years169.98264.97130.08179.733,000,34671.0241.78%

Amgen Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.